Frontage Laboratories Inc, a US-based contract development and manufacturing organisation (CDMO) and subsidiary of Frontage Holdings Corporation (HKEX:1521), announced on Thursday that it has commenced operations at its GMP facility.

The facility opened in May 2025 and received GMP validation in October 2025. It is now fully operational with ongoing Clinical Phase III, PPQ batches and small-scale commercial manufacturing.

The company says that this new facility is dedicated to drug development and clinical & commercial manufacturing including sterile, oral solid, and liquid dosage forms. It includes GMP manufacturing rooms per ISO classification, including containment suites for handling high potency compounds, dedicated manufacturing suites for non-sterile products (tablets, capsules, ointments, gels and oral liquids), aseptic suites for sterile products (e.g., vials, syringes, and cartridges), formulation development rooms, and analytical and microbiology laboratories.